Laronde launched out of Flagship Labs this year with a lofty vision: to deliver as many as 100 new RNA medicines over the next 10 years. Now, it’s fueling that goal with a major $440 million round. “The amount of money raised reflects our ambitions. We wanted to build a big company—and we need big money to build a big company,” said Diego Miralles, M.D., CEO of Laronde and a CEO-partner at Flagship Pioneering. The company spent years under the radar at Flagship’s incubator an

Redefining neuroscience research and development with a data-driven precision neuroscience platform to develop targeted therapies for brain diseases Neumora’s precision data science platform aims to cut through brain disease heterogeneity to match the right patient populations to targeted therapeutics Robust clinical, preclinical and discovery-stage pipeline of eight potential best-in-class precision medicines targeting neuropsychiatric disorders and neurodegenerative disease